iCo Therapeutics Announces Year End 2015 Financial Results

iCo Therapeutics (“iCo” or “the Company”) (TSX-V: ICO) (OTCQX: ICOTF), today reported financial results for the year ended December 31, 2015. Amounts, unless specified otherwise, are expressed in Canadian dollars and presented under International Financial Reporting Standards (“IFRS”).
According to the news:

2015 Financial & Operational Highlights

• Announced the engagement of Corealis Pharma Inc. (“Corealis”) a contract manufacturing organization, for the analytical development, formulation optimization and scale-up of the Oral Amphotericin B Delivery System.  The preparation and regulatory filings for this program are expected to be completed in 2016, with Phase 1A study data available in 2017.
• Strengthened our intellectual property position around the Oral Amphotericin B asset.  iCo now has eleven issued patents related to the technology.
• Our Israeli partner continued to progress iCo-008 in several clinical studies, including commencement of enrollment of patients into a Phase 2 ulcerative colitis study.
• Announced the appointment of Susan Koppy and John Meekison, iCo’s Chief Financial Officer, to iCo’s Board of Directors.

Subsequent to the 2015 year end, it was announced that the Company was undertaking a strategic re-organization in an effort to preserve its asset base and maximize shareholder value.

Click here to view the full story.